Clinical development of targeted fragile X syndrome treatments: An industry perspective

Anna W. Lee, Pamela Ventola, Dejan B Budimirovic, Elizabeth Berry-Kravis, Jeannie Visootsak

Research output: Contribution to journalReview article

Abstract

Fragile X syndrome (FXS) is the leading known cause of inherited intellectual disability and autism spectrum disorder. It is caused by a mutation of the fragile X mental retardation 1 (FMR1) gene, resulting in a deficit of fragile X mental retardation protein (FMRP). The clinical presentation of FXS is variable, and is typically associated with developmental delays, intellectual disability, a wide range of behavioral issues, and certain identifying physical features. Over the past 25 years, researchers have worked to understand the complex relationship between FMRP deficiency and the symptoms of FXS and, in the process, have identified several potential targeted therapeutics, some of which have been tested in clinical trials. Whereas most of the basic research to date has been led by experts at academic institutions, the pharmaceutical industry is becoming increasingly involved with not only the scientific community, but also with patient advocacy organizations, as more promising pharmacological agents are moving into the clinical stages of development. The objective of this review is to provide an industry perspective on the ongoing development of mechanism-based treatments for FXS, including identification of challenges and recommendations for future clinical trials.

Original languageEnglish (US)
Article number214
JournalBrain Sciences
Volume8
Issue number12
DOIs
Publication statusPublished - Dec 1 2018

    Fingerprint

Keywords

  • Clinical trials
  • Drug development
  • Fragile X syndrome
  • Targeted treatments

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this